Download by
Scanning QR Code
No Stock Yet
Loading...
No Stock Yet
No Data
Shares of companies in the broader healthcare sector are trading higher amid overall market strength as stocks rebound following recent weakness.
Shares of companies in the broader healthcare sector are trading higher amid overall market strength as stocks rebound following recent weakness.
Intellia Therapeutics stocks falls for third straight session after Q1 earnings miss
Intellia Therapeutics (NASDAQ:NTLA) shares dropped 9% Monday morning as two brokerages lowered their price targets on the stock. Oppenheimer cut its target on Intellia (NTLA) to $130 from $160, while
Intellia Therapeutics Price Target Cut to $130.00/Share From $160.00 by Oppenheimer
Intellia Therapeutics Price Target Cut to $130.00/Share From $160.00 by Oppenheimer
Intellia Therapeutics Is Maintained at Outperform by Oppenheimer
Intellia Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer Adjusts Intellia Therapeutics' Price Target to $130 From $160, Maintains Outperform Rating
09:14 AM EDT, 05/09/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $130
Oppenheimer analyst Jay Olson maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $160 to $130.
10 Biggest Price Target Changes For Monday
Morgan Stanley cut Guardant Health, Inc. (NASDAQ:GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.Oppenheimer cut the price target for Relmada The
Intellia Therapeutics analyst ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2022 131.24% JMP Securities $165 → $110 Maintains Market Outperform 05/06/2022 106.01% Credit Suisse
JMP Securities Maintains Market Outperform on Intellia Therapeutics, Lowers Price Target to $110
JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and lowers the price target from $165 to $110.
Intellia Therapeutics price target lowered to $130 from $160 at Oppenheimer
Oppenheimer analyst Jay Olson lowered the firm's price target on Intellia Therapeutics to $130 from $160 and keeps an Outperform rating on the shares after the company reported quarterly results and p